2026 Q1 Portfolio Activity
In 2026 Q1, GordonMD Global Investments LP maintained a portfolio of 16 distinct positions. The most significant new addition was SCHOLAR ROCK HLDG CORP, now representing 4.54% of the total fund value. They heavily accumulated shares in VIR BIOTECHNOLOGY INC, increasing the position by 63.2%. The fund also reduced its exposure to CRINETICS PHARMACEUTICALS IN by 43.3%.
Position History
hover any row below to update
Loading…
Total Positions
16
Quarter
2026 Q1
Top Holding
KYTX (25.5%)
Top 10 Concentration
82.4%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-16 of 16
GordonMD Global Investments LP Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
KYTX
KYVERNA THERAPE...
|
Healthcare | 25.51% | 29.60% |
#1
Prev: #1
|
6.5 |
—
|
-147,000 | -3.3% |
P
S
|
4,244,818 | $36,632,779 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TSHA
TAYSHA GENE THE...
|
Healthcare | 15.47% | 5.25% |
#2
5
Prev: #7
|
5.5 |
—
|
-593,351 | -44.6% |
P
S
|
737,550 | $22,215,006 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VIR
VIR BIOTECHNOLO...
|
Healthcare | 9.48% | 4.02% |
#3
5
Prev: #8
|
7.8 |
—
|
588,235 | 63.2% |
P
S
|
1,518,552 | $13,606,226 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BLCO
BAUSCH PLUS LOM...
|
Healthcare | 6.35% | 7.51% |
#4
1
Prev: #3
|
3.5 |
—
|
-40,000 | -6.5% |
P
S
|
573,472 | $9,118,205 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
AMGN
AMGEN INC
|
Healthcare | 4.95% | 5.45% |
#5
Prev: #5
|
3.0 |
—
|
-3,000 | -12.9% |
P
S
|
20,212 | $7,111,592 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SRRK
SCHOLAR ROCK HL...
|
Healthcare | 4.54% | — |
#6
Prev: #—
|
5.3 |
—
|
132,500 | — |
NEW
|
132,500 | $6,513,700 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
RARE
ULTRAGENYX PHAR...
|
Healthcare | 4.22% | 5.43% |
#7
1
Prev: #6
|
2.2 |
—
|
-40,000 | -12.2% |
P
S
|
289,101 | $6,056,666 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PYXS
PYXIS ONCOLOGY ...
|
Healthcare | 4.19% | 3.40% |
#8
4
Prev: #12
|
2.7 |
—
|
no change | no change |
P
S
|
4,121,870 | $6,017,930 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TEVA
TEVA PHARMACEUT...
|
Healthcare | 3.91% | 17.22% |
#9
7
Prev: #2
|
4.6 |
—
|
487,945 | 63.4% |
P
S
|
1,257,495 | $5,621,003 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SION
SIONNA THERAPEU...
|
Healthcare | 3.80% | — |
#10
Prev: #—
|
5.0 |
—
|
136,000 | — |
NEW
|
136,000 | $5,452,240 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 3.76% | 3.32% |
#11
2
Prev: #13
|
2.5 |
—
|
no change | no change |
P
S
|
170,307 | $5,402,138 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
INSM
INSMED INC
|
Healthcare | 3.26% | 3.57% |
#12
1
Prev: #11
|
2.3 |
—
|
no change | no change |
P
S
|
28,587 | $4,674,546 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CRNX
CRINETICS PHARM...
|
Healthcare | 3.21% | 7.48% |
#13
9
Prev: #4
|
1.3 |
—
|
-97,150 | -43.3% |
P
S
|
126,985 | $4,612,095 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
INCY
INCYTE CORP
|
Healthcare | 2.84% | 3.86% |
#14
4
Prev: #10
|
1.1 |
—
|
-11,200 | -20.6% |
P
S
|
43,300 | $4,075,396 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ALLO
ALLOGENE THERAP...
|
Healthcare | 2.43% | — |
#15
Prev: #—
|
4.5 |
—
|
1,430,000 | — |
NEW
|
1,430,000 | $3,489,200 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 2.09% | 3.91% |
#16
7
Prev: #9
|
0.8 |
—
|
-24,000 | -36.0% |
P
S
|
42,680 | $2,994,002 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 |
Showing 1-16 of 16 holdings